Drug Trial Radar · NCT06232096
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Last checked: Nov 19, 2026Latest source record: Mar 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
Feb 22, 2024
Primary completion
Feb 2026
Study completion Mar 2028
Sponsor
- Lead sponsor
- Beijing Mabworks Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized antibody, MBS314, administered by intravenous (IV) infusion in participants with relapsed or refractory multiple myeloma. This entry-to-human study is divided in 2 parts: a dose escalation part (Phase Ⅰa) and an expansion part (Phase Ⅰb/Ⅱ).
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
MBS314 InjectionDrug
Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg \~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms. Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia:Percentage of Participants with Adverse Events (AEs) .Time frame: From Baseline up to approximately 29 months
- Phase Ia:Incidence of Dose Limiting Toxicities (DLTs)Time frame: From Baseline up to 4 weeks
- Phase Ia:Maximum Tolerated Dose (MTD) of MBS314Time frame: Up to approximately 11 months
- Phase Ia:Recommended Phase Ⅱ Dose (RP2D) of MBS314Time frame: Up to approximately 29 months
- Phase Ib/Ⅱ :Efficacy: Overall Response Rate (ORR) as Assessed by Independent Review Committee (IRC)Time frame: Up to approximately 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology and Blood Diseases Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.